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Correspondence 
 
In a comprehensive analysis, Reynolds and colleagues1 have recently reported that 
RGD-mimetic agents such as cilengitide may, under certain experimental conditions, 
promote rather than inhibit angiogenesis. They accordingly express their reservation 
regarding the clinical exploration of such agents in human cancer patients.  
Based on promising phase II data,2,3 cilengitide in combination with temozolomide-
based radiochemotherapy is currently being explored in a phase III registration trial 
for newly diagnosed glioblastoma with O6-methylguanine methyltransferase promoter 
methylation (CENTRIC trial, EORTC 26071-22072). This novel paradigm of seeking 
approval for a first-in-class agent in a molecularly defined subpopulation of 
glioblastoma patients was based on the observation that the apparent clinical benefit 
derived from cilengitide in the phase II trial was prominent only in this patient 
population.2 Do the novel preclinical data raise serious concerns regarding 
paradoxical effects of cilengitide in human glioma patients in vivo? We believe that 
this may not be the case. 
First, the clinical significance of the models used may be questioned. Although the 
major target disease of the current clinical development of cilengitide is glioblastoma, 
no glioma model was studied.  
Second, in vitro analyses suggest that there are multiple actions of cilengitide which 
mediate a clinical benefit in glioblastoma, including direct cytolytic effects on tumor 
cells, cytolytic effects on endothelial cell, and inhibition of cell adhesion, migration 
and invasion.4 While the functional consequences of the interactions of cilengitide 
with its target integrins are likely complex in the context of glioma biology, the overall 
net effect in the clinic appears to be growth-inhibitory rather than growth-promoting.3  
Third, in the current clinical setting, cilengitide is used in combination with 
chemotherapy and radiotherapy, again based on preclinical data showing strong 
sensitization to radiotherapy in rodent glioma models.5 
Fourth, pulse treatment as used in the clinical trials did not result in adverse effects in 
any of the models studied by Reynolds and colleagues.1 In fact, the scheduling 
claimed to be tumor growth-promoting here1 is not used in human patients.  
Fifth, cilengitide used at flat doses of 2000 mg results in peak plasma levels > 200 
micromolar which by magnitudes exceed the concentrations shown here1 to promote 
angiogenesis. In fact, simulations based on population pharmacokinetic models 
demonstrate that concentrations in the angiogenesis-promoting range (0.2-20 
nanomolar)1 are not reached in 75% of patients treated with biweekly i.v. infusions of 
2000 mg cilengitide (data on file, Merck KGaA, Darmstadt, Germany). Micromolar 
concentrations of cilengitide have also been measured in the tumor tissue of glioma 
patients exposed to the drug prior to surgery for recurrent disease.6 Admittedly, the 
extent of blood brain and blood tumor barrier penetration of cilengitide in human 
glioma patients remains uncertain, and it remains uncertain whether potentially pro-
angiogenic concentrations of cilengitide may be operational at least transiently in the 
tumor tissue. 
Sixth and finally, while the authors suggests that cilengitide mediates angiogenesis 
by enhancing the effect of vascular endothelial-derived growth factor (VEGF), the 
striking neuroradiological responses to cilengitide seen in some glioblastoma 
patients7,8 resemble morphologically closely the effects of VEGF-antagonizing agents 
such as bevacizumab.9 Based on these considerations, we acknowledge that 
Reynolds and colleagues1 have assembled an interesting and unexpected set of data 
in preclinical models. In fact, the paradoxical mechanism of a pro-angiogenic effect of 
cilengitide may even be operative in certain settings and contribute to an anti-tumor 
effect of cilengitide in combination with radiotherapy or chemotherapy. This 
consideration relates to the vascular normalization effect of antiangiogenic agents 
which we have proposed to underlie the preferential clinical benefit apparently seen 
in glioblastoma patients with MGMT promoter methylation.2 The clinical significance, 
however, of the complex effects of cilengitide reported by Reynolds and colleagues1 
as well as Alghisi and colleagues10 can only be assessed in appropriately designed 
clinical trials. 
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